• iRhythm highlighted 1Q26 revenue of USD 199.4 million, up 25.7% year over year; adjusted EBITDA margin of 7.1%.
• Maintained 2026 net revenue outlook of USD 875 million to USD 885 million; guided to 12% to 13% adjusted EBITDA margin.
• Outlined expected H1’27 launch for Zio MCT, a next-generation mobile cardiac telemetry patch not yet FDA cleared.
• Reported about 40% penetration in the core U.S. ambulatory cardiac monitoring market; cited 72% share in long-term continuous monitoring.
• Emphasized growth priorities in primary care, international expansion, and adjacent programs including obstructive sleep apnea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iRhythm Technologies Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.